{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T09:41:09Z","timestamp":1782639669853,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejca.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T01:19:46Z","timestamp":1629422386000},"page":"70-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor\u2013positive metastatic breast cancer: Patient-reported outcomes in the PEARL study"],"prefix":"10.1016","volume":"156","author":[{"given":"Zsuzsanna","family":"Kahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-2718","authenticated-orcid":false,"given":"Miguel","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Margeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u00f6szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraf\u00edn","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-0241","authenticated-orcid":false,"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"de la Haba-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-8234","authenticated-orcid":false,"given":"Manuel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel \u00c1lvarez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Gal-Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Garcia-Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Gonz\u00e1lez-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar A.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-4519","authenticated-orcid":false,"given":"Sonia","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Corsaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Rodrig\u00e1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.07.004_bib1","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2021.07.004_bib2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.004_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.004_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","article-title":"Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life","volume":"17","author":"Jacobs","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2021.07.004_bib8","first-page":"1519","article-title":"Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life","volume":"25","author":"Rha","year":"2017","journal-title":"Support Care Canc"},{"key":"10.1016\/j.ejca.2021.07.004_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/14737167.2014.949243","article-title":"The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective","volume":"14","author":"Gupta","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ejca.2021.07.004_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib11","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical Benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.004_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.07.004_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.07.004_bib15","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","article-title":"The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study","volume":"14","author":"Sprangers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2021.07.004_bib17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0959-8049(01)00127-7","article-title":"Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30","volume":"37","author":"Fayers","year":"2001","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.07.004_bib18","unstructured":"EQ-5D-3L USER GUIDE, Version 6.0 updated December 2018. In. Available from: https:\/\/euroqol.org\/publications\/user-guides\/."},{"key":"10.1016\/j.ejca.2021.07.004_bib19","first-page":"93","article-title":"The Spanish VAS tariff based on valuation of EQ-5D health states from the general population","volume":"vols. 2\u20133","author":"Badia","year":"1997"},{"key":"10.1016\/j.ejca.2021.07.004_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.07.004_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib22","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-017-4404-4","article-title":"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced\/metastatic breast cancer","volume":"166","author":"Wilson","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.07.004_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1185\/03007995.2014.887002","article-title":"Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer","volume":"30","author":"Andre","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2021.07.004_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40487-016-0033-z","article-title":"Real-world treatment patterns for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Europe and the United States","volume":"4","author":"Caldeira","year":"2016","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ejca.2021.07.004_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2016.10.021","article-title":"Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis","volume":"31","author":"Bonotto","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2021.07.004_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-019-05190-3","article-title":"Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer","volume":"175","author":"Zhang","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.07.004_bib29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","article-title":"Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value\u00a0sets from seven countries","volume":"36","author":"Janssen","year":"2018","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ejca.2021.07.004_bib30","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.004_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113265","article-title":"Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (KCSG-BR 15-10)","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2021.07.004_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1006449315650","volume":"18","author":"Budman","year":"2000","journal-title":"Capecitabine. Invest New Drugs"},{"key":"10.1016\/j.ejca.2021.07.004_bib33","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/annonc\/mdq069","article-title":"Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?","volume":"21","author":"Zielinski","year":"2010","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:38Z","timestamp":1760733158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"alternative-id":["S0959804921004408"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor\u2013positive metastatic breast cancer: Patient-reported outcomes in the PEARL study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}